Oxaliplatin-induced Acute Neurotoxicity Recovers Between Repeat Infusion Cycles: An Axonal Excitability Repeated Multiple Measurements Study.

Autor:	Kokotis P; Laboratory of Clinical Neurophysiology, First Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Papantoniou M; Laboratory of Clinical Neurophysiology, First Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Carr RW; Department of Experimental Pain Research, MCTN Mannheim, University of Heidelberg, Heidelberg, Germany., Schmelz M; Department of Experimental Pain Research, MCTN Mannheim, University of Heidelberg, Heidelberg, Germany., Siakavella D; Department of Neurology, KAT Hospital, Athens, Greece., Skafida E; Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece., Papadimitriou C; Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Jazyk:	angličtina
Zdroj:	Cancer diagnosis & prognosis [Cancer Diagn Progn] 2024 May 03; Vol. 4 (3), pp. 320-325. Date of Electronic Publication: 2024 May 03 (Print Publication: 2024).
DOI:	10.21873/cdp.10327
Abstrakt:	Background/aim: Oxaliplatin, a platinum-based chemotherapy used in the treatment of colorectal cancer, induces acute neurotoxicity following infusion. The aim of this study was to establish whether alterations in axonal excitability develop progressively with higher cumulative doses and whether there is a recovery in motor axons after each cycle of treatment. Patients and Methods: Twenty consecutive patients with a colorectal cancer diagnosis, referred from the Oncology Department of Aretaieion Hospital of Athens, were enrolled in this study between October 2018 and May 2019. None of the participants had diabetes, alcohol abuse, known neuropathy or were previously treated with another neo-adjuvant therapy. Threshold Tracking techniques and Qtrac software were used for assessing axonal excitability in motor axons. Excitability recordings were undertaken before and immediately after the end of oxaliplatin infusion. Results: Statistically significant changes were found (p<0.01) in axonal excitability (relative refractory period, refractoriness at 2 ms and 2.5 ms, sub-excitability and super-excitability) before and after oxaliplatin infusion. No statistically significant changes (p>0.05) were found in threshold electrotonus and strength-duration parameters before and after oxaliplatin infusion. We also did not find statistically significant differences (p>0.05) between means of excitability parameters before infusion at each cycle. Conclusion: Our study confirms oxaliplatin-induced acute neurotoxicity following infusion and suggests that motor axons recover between repeat infusion cycles. Competing Interests: The Authors have no conflicts of interest to declare in relation to this study. (Copyright 2024, International Institute of Anticancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu